NCT05453500PHASE2ACTIVE_NOT_RECRUITING
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Sponsor · University of WashingtonCondition · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeIntervention · Cyclophosphamide, DoxorubicinUpdated May 2026
NCT07582159PHASE2NOT_YET_RECRUITING
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor · City of Hope Medical CenterCondition · Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaIntervention · Acalabrutinib, Biospecimen CollectionUpdated May 2026
NCT05718869PHASE2ACTIVE_NOT_RECRUITING
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Sponsor · City of Hope Medical CenterCondition · Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaIntervention · Biospecimen Collection, Bone Marrow BiopsyUpdated May 2026
NCT04978584PHASE2ACTIVE_NOT_RECRUITING
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
Sponsor · M.D. Anderson Cancer CenterCondition · Diffuse Large B-Cell LymphomaIntervention · Acalabrutinib, CyclophosphamideUpdated May 2026
NCT05786040PHASE2RECRUITING
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Sponsor · Timothy VoorheesCondition · Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative DisorderIntervention · Biopsy, Biospecimen CollectionUpdated Apr 2026
NCT07502872PHASE2NOT_YET_RECRUITING
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Sponsor · Brown UniversityCondition · Diffuse Large B Cell Lymphoma, High-grade B-cell LymphomaIntervention · Tafasitamab, Polatuzumab vedotinUpdated Mar 2026
NCT05455697PHASE1, PHASE2RECRUITING
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Sponsor · University of WashingtonCondition · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular LymphomaIntervention · Bone Marrow Biopsy, CyclophosphamideUpdated Dec 2025
NCT05821088PHASE2RECRUITING
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Sponsor · David Bond, MDCondition · Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedIntervention · Biopsy, Biospecimen CollectionUpdated Nov 2025
NCT05943496PHASE1RECRUITING
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Sponsor · OHSU Knight Cancer InstituteCondition · Chronic Lymphocytic LeukemiaIntervention · Acalabrutinib, Biospecimen CollectionUpdated Nov 2025
NCT05890352PHASE2RECRUITING
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Sponsor · SWOG Cancer Research NetworkCondition · Grade 3b Follicular Lymphoma, High Grade B-Cell LymphomaIntervention · Biospecimen Collection, Computed TomographyUpdated Oct 2025
NCT05910801PHASE2RECRUITING
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Sponsor · Academic and Community Cancer Research UnitedCondition · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaIntervention · Biopsy, Biospecimen CollectionUpdated Nov 2024
NCT05993611PHASE1SUSPENDED
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Sponsor · City of Hope Medical CenterCondition · Chronic Graft Versus Host Disease, Hematologic and Lymphocytic DisorderIntervention · Biopsy, Biospecimen CollectionUpdated Nov 2025
NCT05626322PHASE1, PHASE2TERMINATED
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor · PfizerCondition · Diffuse Large B-Cell LymphomaIntervention · Maplirpacept, TafasitamabUpdated Sep 2025